| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.02. | Anortech Inc: Anortech files provisional patent in U.S. | ||
| 11.02. | AnorTech Inc.: AnorTech Files Provisional Patent for Sustainable Smelter Grade Alumina Production | ||
| 13.12.24 | Anortech Inc: Anortech shares to start trading on OTCQB Dec. 16 | ||
| 12.12.24 | AnorTech Inc.: AnorTech Upgrades OTC Listing to OTCQB Market | VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. ("AnorTech" or the "Company") (TSX Venture Exchange "ANOR"; OTC "HUDRF") is pleased to announce that it has received approval... ► Artikel lesen | |
| 06.09.24 | Anortech Inc: Anortech grants options to buy 4.95 million shares |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | JPMorgan Emerg. EMEA - Russian Court Order | ||
| 13.02. | SMALL-CAP WINNERS & LOSERS: Peace hope lifts JPMorgan Emerging Europe | ||
| 12.02. | JPMorgan Emerg. EMEA - Ten Largest Investments | ||
| 04.02. | JPMorgan EMEA beats benchmark but still overshadowed by events in Russia | ||
| 04.02. | JPMorgan Emerg. EMEA - Notification of Board Change |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.02. | BMO cuts Q32 Bio stock rating, slashes price target to $3 | ||
| 11.02. | Q32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitor | ||
| 11.02. | Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target | ||
| 10.02. | Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata | -- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating... ► Artikel lesen | |
| 10.02. | Q32 Bio Inc. - 8-K, Current Report |
| Unternehmen / Aktien | Kurs | % |
|---|---|---|
| ANORTECH INC | 0,012 | 0,00 % |
| JPMORGAN EMERGING EUROPE MIDDLE EAST & AFRICA SECURITIES PLC | 1,420 | 0,00 % |
| Q32 BIO INC | 2,280 | -7,32 % |
